Modality
Radioligand
MOA
CAR-T BCMA
Target
LAG-3
Pathway
Fibrosis
Wet AMD
Development Pipeline
Preclinical
~Mar 2019
→ ~Jun 2020
Phase 1
~Sep 2020
→ ~Dec 2021
Phase 2
~Mar 2022
→ ~Jun 2023
Phase 3
~Sep 2023
→ ~Dec 2024
NDA/BLA
Mar 2025
→ Mar 2030
NDA/BLACurrent
NCT07879502
635 pts·Wet AMD
2025-03→2030-03·Recruiting
635 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-03-224.0y awayPh3 Readout· Wet AMD
Trial Timeline
Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2
NDA/BLA
Recruit…
Catalysts
Ph3 Readout
2030-03-22 · 4.0y away
Wet AMD
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07879502 | NDA/BLA | Wet AMD | Recruiting | 635 | OS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Voxacilimab | Pfizer | Phase 2 | TYK2 | |
| ABB-3060 | AbbVie | Phase 2 | LAG-3 | |
| NVO-9087 | Novo Nordisk | Phase 1/2 | Tau | |
| Polazasiran | Amgen | Phase 2 | LAG-3 | |
| Fixazanubrutinib | Amgen | Phase 2 | PI3Kα | |
| REG-8074 | Regeneron | Phase 2/3 | KRASG12C | |
| ALN-6288 | Alnylam | Approved | LAG-3 | |
| Sovarelsin | Alnylam | Phase 2/3 | LAG-3 | |
| JAZ-8729 | Jazz Pharma | Phase 2/3 | FcRn | |
| ACA-2691 | Acadia Pharma | Phase 3 | BCMA |